# Title

 Food and Drugs. PART 212â€”CURRENT GOOD MANUFACTURING PRACTICE FOR POSITRON EMISSION TOMOGRAPHY DRUGS


# ID

 CFR-2018-title21-vol4.Pt. 212


# Structured Analysis Summary

| Type        | Values                                                                                                                                                                                                                                                                                     |
|:------------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Constraints | ['before', 'after', 'prior to', 'minimum', 'at least', 'within']                                                                                                                                                                                                                           |
| Duration    | ['1.0 year', '30.0 hour']                                                                                                                                                                                                                                                                  |
| Condition   | ['when', 'if', 'until', 'where']                                                                                                                                                                                                                                                           |
| Entities    | ['Strength', 'Rockville, MD', 'Equipment', 'Sterility', 'Final', 'Acceptance', 'Batch', 'Master', 'United States Pharmacopeia', 'Quality', 'Documentation', 'Laboratory', 'Food', 'United States Pharmacopeial Convention, Inc', 'Inactive', 'Process', 'Material', 'Lot', 'Verification'] |
| Date        | ['2009-05-01']                                                                                                                                                                                                                                                                             |


# Structured Analysis With Context

 


## Constraints

| Constraints   | Context                                                                                                                  |
|:--------------|:-------------------------------------------------------------------------------------------------------------------------|
| within        | drug intended to have uniform character and quality, within specified limits, that is produced according to a            |
| prior to      | Conditional final release means a final release made  prior to completion of a required finished-product test because of |
| within        | of a batch, having uniform character and quality within  specified limits.                                               |
| within        | that ensures its having uniform character and quality within  specified limits.                                          |
| within        | of PET drug having uniform character and quality, within specified limits, that is produced during one succession        |
| minimum       | good manufacturing practice for PET drugs is the minimum requirements for the methods to be used in,                     |
| before        | You must approve or reject,  before implementation, any initial specifications, methods, processes, or procedures,       |
| before        | the components used to make the inactive ingredient before  the components are released for use.                         |
| at least      | You must perform  at least a visual identification of each lot of containers                                             |
| minimum       | of action limits on radiochemical yield, i.e., the minimum percentage of yield beyond which investigation and corrective |
| before        | be checked to ensure cleanliness and suitability immediately before  use.                                                |
| before        | accuracy, sensitivity, specificity, and reproducibility of the procedure. before                                         |
| before        | drug product conforms to specifications, except for sterility. before                                                    |
| before        | For a PET drug product produced in sub-batches,  before final release, you must conduct an appropriate laboratory        |
| before        | Sterility testing need not be completed  before final release but must be started within 30                              |
| within        | completed before final release but must be started within  30 hours after completion of production.                      |
| after         | release but must be started within 30 hours after  completion of production.                                             |
| within        | been obtained if the test had been started within  the 30-hour time period.                                              |
| after         | complete the omitted test using the reserve sample after the malfunction is corrected, and document that reasonable      |
| before        | product must conform to specifications, except for sterility, before  final release.                                     |
| at least      | referenced in this part for a period of at least 1 year from the date of final release,                                  |


## Duration

| Duration   | Context                                                                                                                                                                                                                                                                                                        |
|:-----------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 30.0 hour  | Sterility testing need not be completed before final release but must be started within 30 hours after completion of production.                                                                                                                                                                               |
| 30.0 hour  | The 30-hour requirement may be exceeded due to a weekend or holiday.                                                                                                                                                                                                                                           |
| 30.0 hour  | If the sample for sterility testing is held longer than 30 hours, you must demonstrate that the longer period does not adversely affect the sample and the test results obtained will be equivalent to test results that would have been obtained if the test had been started within the 30-hour time period. |
| 30.0 hour  | If the sample for sterility testing is held longer than 30 hours, you must demonstrate that the longer period does not adversely affect the sample and the test results obtained will be equivalent to test results that would have been obtained if the test had been started within the 30-hour time period. |
| 1.0 year   | You must maintain all records and documentation referenced in this part for a period of at least 1 year from the date of final release, including conditional final release, of a PET drug product.                                                                                                            |


## Condition

| Condition   | Context                                                                                                                   |
|:------------|:--------------------------------------------------------------------------------------------------------------------------|
| when        | Other definitions of these words may apply  when they are used in other parts of this                                     |
| when        | or other material used in PET drug production, when tested according to the described analytical procedures, meets        |
| when        | determine the need for an investigation, conduct investigations when  necessary, and take appropriate corrective actions. |
| when        | drug, or give erroneous or invalid test results when improperly used or maintained, is clean, suitable for                |
| if          | any lot that does not meet its spec if ications, including any expiration date                                            |
| if          | that PET drug product complies with written spec if ications by examining a cert                                          |
| if          | inactive ingredient used in that PET drug product. if                                                                     |
| if          | determine that each lot complies with written spec if ications by examining a cert                                        |
| if          | However,  if you use as an inactive ingredient a product                                                                  |
| if          | components designated by names and codes sufficiently spec if ic to indicate any special quality characteristic; (4)      |
| if          | are permitted in the amount of component necessary if  they are spec                                                      |
| until       | materials to ensure that the materials are controlled until required tests or other verification activities have been     |
| when        | are not fully verified through finished-product testing or when only the initial sub-batch in a series is                 |
| when        | are not fully verified through finished-product testing or when only the initial sub-batch in a series is                 |
| where       | What requirements apply to the laboratories  where I test components, in-process materials, and finished PET              |
| if          | You must establish spec if ications for each PET drug product, including criteria                                         |
| until       | PET drug product is not given final release until the following are done: (1) An appropriate laboratory                   |
| if          | to test results that would have been obtained if the test had been started within the 30-hour                             |
| if          | approve the conditional final release of the product if you meet the following conditions: (i) You have                   |
| if          | approve the conditional final release of the product if you meet the following conditions: (i) You have                   |
| if          | approve the conditional final release of the product if you meet the following conditions: (i) You have                   |
| when        | malfunction; (v) If you obtain an out-of-specification result when testing the reserve sample, you immediately notify the |
| if          | (2) Even  if the criteria in paragraph (f)(1) of this section                                                             |
| if          | (2) Even  if the criteria in paragraph (f)(1) of this section                                                             |
| until       | release another batch of the PET drug product until you have corrected the problem concerning the malfunction             |
| if          | What actions must I take  if a batch of PET drug product does not                                                         |
| if          | What do I do  if I receive a complaint about a PET drug                                                                   |


## Entities

| Entities                                    | Context                                                                                                                                                  |
|:--------------------------------------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------|
| Food                                        | Food  and Drugs.                                                                                                                                         |
| Acceptance                                  | Acceptance criteria means numerical limits, ranges, or other criteria                                                                                    |
| Batch                                       | Batch means a specific quantity of PET drug intended                                                                                                     |
| Batch                                       | Batch production and control record means a unique record                                                                                                |
| Final                                       | Final release means the authoritative decision by a responsible                                                                                          |
| Inactive                                    | Inactive ingredient means any intended component of the PET                                                                                              |
| Lot                                         | Lot means a batch, or a specifically identified portion                                                                                                  |
| Lot                                         | Lot number, control number, or batch number means any                                                                                                    |
| Master                                      | Master production and control record means a compilation of                                                                                              |
| Material                                    | Material release means the authoritative decision by a responsible                                                                                       |
| Quality                                     | Quality assurance means a system for ensuring the quality                                                                                                |
| Strength                                    | Strength means the concentration of the active pharmaceutical ingredient                                                                                 |
| Verification                                | Verification means confirmation that an established method, process, or                                                                                  |
| United States Pharmacopeia                  | of the  United States Pharmacopeia  (USP) National Formulary (NF) (USP 32/NF 27) (2009).                                                                 |
| United States Pharmacopeial Convention, Inc | You may obtain a copy from the  United States Pharmacopeial Convention, Inc ., 12601 Twinbrook Pkwy., Rockville, MD 20852, Geeta                         |
| Rockville, MD                               | United States Pharmacopeial Convention, Inc., 12601 Twinbrook Pkwy., Rockville, MD 20852, Geeta M. Tirumalai, 301-816-8352, e-mail: gt@usp.org, Internet |
| Equipment                                   | Equipment must be constructed and maintained so that surfaces                                                                                            |
| Batch                                       | (c)  Batch  production and control records.                                                                                                              |
| Process                                     | Process controls must include control of in-process materials to                                                                                         |
| Process                                     | Process  verification activities and results must be documented.                                                                                         |
| Documentation                               | Documentation must include the date and signature of the                                                                                                 |
| Laboratory                                  | Laboratory analytical methods must be suitable for their intended                                                                                        |
| Sterility                                   | Sterility testing need not be completed before final release                                                                                             |


## Date

| Date       | Context                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|:-----------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 2009-05-01 | For investigational PET drugs for human use produced under an investigational new drug application in accordance with part 312 of this chapter, and PET drugs produced with the approval of a Radioactive Drug Research Committee in accordance with part 361 of this chapter, the requirement under the act to follow current good manufacturing practice is met by complying with the regulations in this part or by producing PET drugs in accordance with Chapter 823, &#8220;Radiopharmaceuticals for Positron Emission Tomography&#8212;Compounding,&#8221; May 1, 2009, pp. |


